U.S. markets open in 7 hours 46 minutes

Mirum Pharmaceuticals, Inc. (MIRM)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
18.93+0.03 (+0.16%)
At close: 4:00PM EDT

Mirum Pharmaceuticals, Inc.

950 Tower Lane
Suite 1050
Foster City, CA 94404
United States
650 667 4085

Full Time Employees68

Key Executives

NameTitlePayExercisedYear Born
Mr. Christopher PeetzPres, CEO & Director785.22kN/A1979
Dr. Ian ClementsChief Financial Officer541.15kN/A1969
Mr. Peter Radovich M.B.A., Ph.D.Chief Operating Officer524.85kN/A1978
Dr. Pamela Vig Ph.D.Chief Scientific OfficerN/AN/A1971
Mr. Paul K. RossChief Compliance OfficerN/AN/AN/A
Ms. Lara Longpre MSC, MBAChief Devel. OfficerN/AN/A1970
Dr. Edwin Jonathan Tucker M.D.Chief Medical OfficerN/AN/A1972
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company's lead product candidate is Maralixibat, an investigational oral drug that is in Phase 3 clinical trial for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It is also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. The company was incorporated in 2018 and is headquartered in Foster City, California.

Corporate Governance

Mirum Pharmaceuticals, Inc.’s ISS Governance QualityScore as of April 30, 2021 is 8. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.